Dr. Patrick D. Yao, DO

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $5,366,095 in research payments for these studies, mostly to the institutions running them.

• A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Healthy Subjects
  Vertex Pharmaceuticals Incorporated
• A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX 993 IV in Healthy Subjects
  Vertex Pharmaceuticals Incorporated
• A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Extension Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of VX-407 in Healthy Subjects
  Vertex Pharmaceuticals Incorporated
• A Phase 1, Two-part, Open-label Single Ascending Dose Study to Evaluate Safety, Tolerability,and Pharmacokinetics of BMS-986365, Food and Proton Pump Inhibitor Effects, and RelativeBioavailability of BMS-986365 Capsul…
  E.r. Squibb & Sons, L.l.c.
• A Phase 1, Single-blind, Randomized, Parallel-group Study in Healthy Participants to Investigate the Single-dose Pharmacokinetics, Safety and Tolerability of Rilpivirine After Subcutaneous Administration of a Rilpivir…
  Janssen Research & Development, LLC
• A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
  E.r. Squibb & Sons, L.l.c. · Completed · NCT07118215
• A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
  E.r. Squibb & Sons, L.l.c. · Recruiting · NCT07204418
• A Phase 1, 3-part, Open-label Study to Evaluate the Effects of KarXT Administration on the Pharmacokinetics of Midazolam, Fexofenadine, and Digoxin in Healthy Adult Participants
  E.r. Squibb & Sons, L.l.c.
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Family Medicine clinicians in Olathe

• Reem M. Alam, MD
• Mariah J. Andrews, MD
• Robert Andrews, MD
• Christian A. Bell, DO
• Gary D. Bernhardt, M.D.
• Lauren J. Bessey, DO
• Peter A. Bock, M.D.
• Peter A. Burgos, M.D.